A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168

Phase 1 Completed 16 enrolled Amgen

Non-randomizedSequentialOpen-labelBasic science

Summary

The primary objective of this clinical trial is to evaluate the effect of a high-fat, high-calorie meal on the pharmacokinetic (PK) profile of CCX168, following oral administration of a single dose of 30 mg CCX168 to healthy volunteers.

Timeline

Start: 2015-12-03
Primary completion: 2016-02-09
Completion: 2016-05-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Avacopan	Small molecule	3 mg	Oral
Subject	Avacopan	Small molecule	30 mg	Oral
Subject	Avacopan	Small molecule	100 mg	Oral

A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168

Summary

Timeline

Drugs

Indications